Hypocretin/Orexin Peptides Alter Spike Encoding by Serotonergic Dorsal Raphe Neurons through Two Distinct Mechanisms That Increase the Late Afterhyperpolarization.
Orexins (hypocretins) are neuropeptides that regulate multiple homeostatic processes, including reward and arousal, in part by exciting serotonergic dorsal raphe neurons, the major source of forebrain serotonin. Here, using mouse brain slices, we found that, instead of simply depolarizing these neurons, orexin-A altered the spike encoding process by increasing the postspike afterhyperpolarization (AHP) via two distinct mechanisms. This orexin-enhanced AHP (oeAHP) was mediated by both OX1 and OX2 receptors, required Ca(2+) influx, reversed near EK, and decayed with two components, the faster of which resulted from enhanced SK channel activation, whereas the slower component decayed like a slow AHP (sAHP), but was not blocked by UCL2077, an antagonist of sAHPs in some neurons. Intracellular phospholipase C inhibition (U73122) blocked the entire oeAHP, but neither component was sensitive to PKC inhibition or altered PKA signaling, unlike classical sAHPs. The enhanced SK current did not depend on IP3-mediated Ca(2+) release but resulted from A-current inhibition and the resultant spike broadening, which increased Ca(2+) influx and Ca(2+)-induced-Ca(2+) release, whereas the slower component was insensitive to these factors. Functionally, the oeAHP slowed and stabilized orexin-induced firing compared with firing produced by a virtual orexin conductance lacking the oeAHP. The oeAHP also reduced steady-state firing rate and firing fidelity in response to stimulation, without affecting the initial rate or fidelity. Collectively, these findings reveal a new orexin action in serotonergic raphe neurons and suggest that, when orexin is released during arousal and reward, it enhances the spike encoding of phasic over tonic inputs, such as those related to sensory, motor, and reward events.



Orexin peptides are known to excite neurons via slow postsynaptic depolarizations. Here we elucidate a significant new orexin action that increases and prolongs the postspike afterhyperpolarization (AHP) in 5-HT dorsal raphe neurons and other arousal-system neurons. Our mechanistic studies establish involvement of two distinct Ca(2+)-dependent AHP currents dependent on phospholipase C signaling but independent of IP3 or PKC. Our functional studies establish that this action preserves responsiveness to phasic inputs while attenuating responsiveness to tonic inputs. Thus, our findings bring new insight into the actions of an important neuropeptide and indicate that, in addition to producing excitation, orexins can tune postsynaptic excitability to better encode the phasic sensory, motor, and reward signals expected during aroused states.
Department of Physiology, New York Medical College, Valhalla, New York 10595, and.
Masaru
0000-0002-7413-1359
M
Ishibashi
Department of Physiology, New York Medical College, Valhalla, New York 10595, and.
Iryna
0000-0002-0123-0866
I
Gumenchuk
Department of Physiology, New York Medical College, Valhalla, New York 10595, and.
Kenichi
0000-0002-5802-8845
K
Miyazaki
Department of Life Science and Medical Bioscience, Faculty of Science and Engineering, Waseda University, Tokyo 162-8480, Japan.
Takafumi
0000-0002-2728-0060
T
Inoue
Department of Physiology, New York Medical College, Valhalla, New York 10595, and.
William N
0000-0003-0065-5261
WN
Ross
Department of Physiology, New York Medical College, Valhalla, New York 10595, and chris_leonard@nymc.edu.
Christopher S
0000-0003-4414-1748
CS
Leonard
D000200:Action Potentials / Q000502:physiology*; D000818:Animals; D002478:Cells, Cultured; D065847:Dorsal Raphe Nucleus / Q000502:physiology*; D005260:Female; D017774:Long-Term Potentiation / Q000502:physiology*; D008297:Male; D008564:Membrane Potentials / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008959:Models, Neurological; D000068797:Orexins / Q000378:metabolism*; D059326:Serotonergic Neurons / Q000502:physiology*
D000068797:Orexins
SK channels; arousal; narcolepsy; reward; slow AHP; spike frequency adaptation
J Clin Invest. 2014 Feb;124(2):604-16
24382351
Neuroscientist. 2003 Jun;9(3):181-94
15065814
Neuron. 2006 Feb 16;49(4):589-601
16476667
Neurosci Res. 2005 Jan;51(1):55-65
15596241
J Neurosci. 2007 Oct 3;27(40):10785-96
17913912
FEBS Lett. 2002 Aug 28;526(1-3):11-4
12208495
J Neurosci. 2005 Jan 26;25(4):896-905
15673670
J Neurosci. 2014 Mar 5;34(10):3607-21
24599460
Stress. 2005 Dec;8(4):233-46
16423712
J Neurophysiol. 2003 Apr;89(4):2167-75
12611968
J Neurophysiol. 2004 Jan;91(1):324-35
12917389
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10232-7
20534576
J Neurosci. 1986 Feb;6(2):475-80
3456434
J Neurosci. 2011 Apr 27;31(17):6518-26
21525292
Sleep Med. 2011 Aug;12(7):714-9
21689985
J Neurophysiol. 2009 Nov;102(5):3026-37
19710375
Nature. 1985 Jun 6-12;315(6019):501-3
2582271
J Neurophysiol. 1994 Nov;72(5):2360-7
7884464
J Neurophysiol. 2005 Apr;93(4):2012-20
15548621
Neuropsychopharmacology. 1999 Aug;21(2 Suppl):9S-15S
10432483
Mol Cell Neurosci. 2000 May;15(5):476-93
10833304
Neuroscience. 2000;98(2):295-300
10854760
Neuron. 2004 Sep 16;43(6):847-58
15363395
Brain Res. 1982 Apr 29;238(2):463-9
6284300
J Neurosci. 2011 Dec 14;31(50):18303-12
22171034
Brain Res. 1988 Aug 30;459(1):27-36
3139262
Cell. 1999 Aug 20;98(4):437-51
10481909
Nat Commun. 2016 Jan 28;7:10503
26818705
Sleep Med Rev. 2011 Aug;15(4):269-81
21459634
Pflugers Arch. 1984 Nov;402(3):244-7
6097865
Mol Pharmacol. 2006 Nov;70(5):1494-502
16877678
Curr Opin Pharmacol. 2009 Feb;9(1):39-45
19185540
Eur J Neurosci. 2004 Mar;19(6):1524-34
15066149
Mol Cell Neurosci. 2004 Jul;26(3):458-69
15234350
Cell. 1998 Feb 20;92(4):573-85
9491897
Biophys J. 2008 Jul;95(1):66-87
18375511
J Neurosci. 1998 Dec 1;18(23):9996-10015
9822755
J Neurosci. 2005 Oct 5;25(40):9185-94
16207878
Mol Cell Neurosci. 2004 Dec;27(4):343-69
15555915
Nat Neurosci. 2010 Jan;13(1):53-9
19966842
J Neurosci. 2013 Aug 7;33(32):13025-41
23926257
Trends Pharmacol Sci. 1998 Sep;19(9):370-5
9786025
Eur J Neurosci. 2014 Jan;39(2):186-96
24188044
J Neurosci. 1995 Sep;15(9):6069-76
7666190
Neuropharmacology. 2002 Dec;43(7):1119-28
12504918
J Neurosci. 2001 Dec 1;21(23):9273-9
11717361
J Neurosci. 2014 Apr 2;34(14 ):4809-21
24695701
Eur J Neurosci. 2007 Jan;25(1):119-26
17241273
Eur J Neurosci. 2000 Feb;12(2):726-30
10712652
J Comp Neurol. 2001 Jun 18;435(1):6-25
11370008
J Neurosci. 2002 Nov 1;22(21):9453-64
12417670
J Neurophysiol. 2010 Oct;104(4):2052-62
20719929
Cell. 1999 Aug 6;98(3):365-76
10458611
J Physiol. 1994 Aug 1;478 Pt 3:437-47
7525947
Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):322-7
9419374
J Neurosci. 2002 Oct 15;22(20):8850-9
12388591
Synapse. 1991 Mar;7(3):193-206
1882329
Front Neurosci. 2013 Dec 20;7:246
24391530
Br J Pharmacol. 2014 Jan;171(2):314-31
23902572
Neuron. 2000 Sep;27(3):469-74
11055430
Eur J Neurosci. 2003 Dec;18(12):3155-66
14686890
J Physiol. 1971 Feb;213(1):21-30
5575340
Neuron. 2014 Mar 19;81(6):1360-74
24656254
J Biol Chem. 2010 Aug 6;285(32):25053-61
20538594
Neuron. 2003 Jun 5;38(5):715-30
12797957
Br J Pharmacol. 2014 Jan;171(2):294-313
23848055
Front Cell Neurosci. 2012 Oct 25;6:47
23112761
Br J Pharmacol. 2001 Dec;134(7):1461-6
11724752
J Neurosci. 1997 May 15;17(10):3476-87
9133373
Mol Pharmacol. 2010 Dec;78(6):1088-95
20843955
J Physiol. 1986 Mar;372:245-59
2425084
Neuron. 2005 Jun 2;46(5):787-98
15924864
J Physiol. 2011 Jul 1;589(Pt 13):3211-29
21576272
J Physiol. 1993 Sep;469:387-405
8271204
J Neurophysiol. 2004 Jul;92(1):221-35
14999052
J Neurophysiol. 2008 Oct;100(4):2265-81
18667550
J Neurosci. 2005 Jul 13;25(28):6716-20
16014733
Br J Pharmacol. 2004 Nov;143(6):753-64
15504758
Nat Med. 2000 Sep;6(9):991-7
10973318
J Neurosci. 2007 Feb 28;27(9):2369-76
17329434
Trends Neurosci. 2000 Mar;23(3):131-7
10675918
Neuroscience. 2011 Dec 1;197:200-24
21958868
Eur J Neurosci. 2008 Sep;28(6):1108-15
18783364
J Neurosci. 2002 Feb 1;22(3):666-73
11826096
J Mol Cell Cardiol. 2010 Jan;48(1):201-10
19616555
J Neurophysiol. 2010 May;103(5):2652-63
20237311
Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19974-9
19060215
J Neurosci. 1987 Dec;7(12):3897-906
2826720
J Physiol. 1988 Feb;396:417-33
2457691
FEBS Lett. 1998 Oct 30;438(1-2):71-5
9821961
Mol Pharmacol. 2012 Aug;82(2):156-67
22550093
J Neurosci. 1998 Jul 15;18(14):5366-73
9651219
J Physiol. 2005 Nov 15;569(Pt 1):41-57
16141270
Trends Pharmacol Sci. 1996 Nov;17(11):416-21
8990958
Neuron. 1993 Dec;11(6):1023-35
8274274
J Neurophysiol. 1998 Feb;79(2):1081-91
9463463
J Neurosci. 1988 Sep;8(9):3499-506
3171686
J Neurosci. 2016 Feb 3;36(5):1747-57
26843654
Neural Comput. 2003 Nov;15(11):2523-64
14577853
Toxicon. 2004 Jun 15;43(8):933-49
15208027
Am J Physiol. 1999 Mar;276(3 Pt 1):C648-58
10069992
Br J Pharmacol. 2008 Mar;153 Suppl 1:S379-88
18059321